T1	Participants 143 250	endometriosis patients of a 12-month course of GnRH agonist alone or with one of three "add-back" regimens.
T2	Participants 675 798	Of 201 patients enrolled in the initial trial, 123 completed at least 280 days of therapy and entered the follow-up period.
